-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

702.O1.6 702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells

Symposia: CAR-T Cell Therapies: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Combination therapy, Lymphoid Leukemias, Research, Acute Myeloid Malignancies, AML, Adult, ALL, Fundamental Science, Clinical trials, Translational Research, Lymphomas, Non-Hodgkin lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Chemotherapy, Genomics, Bioinformatics, Clinical Research, Pediatric, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunology, Immunotherapy, Aggressive lymphoma, Lymphoid Malignancies, Non-Biological therapies, Computational biology, Young adult , Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Gene editing, Profiling, Study Population, Human, Pathogenesis, Animal model, Omics technologies, Pathology
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Grand Hall C (Manchester Grand Hyatt San Diego)
Moderators:
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center and Saar Gill, MD, PhD, University of Pennsylvania
Disclosures:
Haubner: Takeda Pharmaceuticals: Patents & Royalties. Gill: Mission Bio: Membership on an entity's Board of Directors or advisory committees; Asher Biotherapeutics: Research Funding; Novartis: Patents & Royalties, Research Funding; Carisma: Current holder of stock options in a privately-held company; Interius: Current holder of stock options in a privately-held company, Research Funding.
This session will focus on CAR T cells for AML and therapies that target myeloid cells to improve CAR T cell outcomes. So, the theme of the session will be the myeloid axis. The selected abstracts will range from correlative science to novel targets in preclinical models.
4:00 PM

David Stahl, MD1*, Philipp Gödel, MD1*, Hyatt Balke-Want, MD1*, Paul Segbers1*, Luis Tetenborg1*, Rahil Gholamipoorfard, PhD2*, Daniel Bachurski, MD1*, France Rose, PhD3*, Zinaida Good, PhD4, Adrian G. Simon, MD5*, Marieke Nill1*, Ruth Flümann, MD1*, Tobias Riet, PhD1*, Janina Dörr, PhD6*, Stuart J. Blakemore, PhD1*, Herrad Baurmann, MD7*, Conrad-Amadeus Voltin, MD8*, Nicole Potter9*, Lilli Schlözer1*, Svenja Wagener-Ryczek5*, Andra-Iza Iuga, MD10*, Jan-Michel Heger, MD1*, Hanna Ludwig, MD1*, Julia K. Schleifenbaum, MD1*, Paul J. Bröckelmann, MD1*, Ron D. Jachimowicz, MD1*, Gero Knittel, PhD11*, Sven Borchmann, MD/PhD1*, Sabine Merkelbach-Bruse, PhD5*, Christian Pallasch, MD1*, Martin Peifer, PhD2*, Mark Nitz, PhD9*, Johannes Brägelmann, MD2*, Werner Müller, PhD7*, Thorsten Persigehl, MD10*, Katarzyna Bozek, PhD3*, Reinhard Büttner, MD5*, Michael J. Hallek, MD1, Sebastian Kobold, MD6*, Markus Chmielewski, PhD1*, Hans Christian Reinhardt, MD12, Crystal L. Mackall, MD4, Nima Abedpour, PhD2*, Peter Borchmann, MD1 and Roland T. Ullrich, MD/PhD1*

1Department 1 of Internal Medicine, University Hospital Cologne, Cologne, Germany
2Department of Translational Genomics, University of Cologne, Cologne, Germany
3Institute for Biomedical Informatics, University of Cologne, Cologne, Germany
4Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
5Institute of Pathology, University Hospital Cologne, Cologne, Germany
6Division of Clinical Pharmacology, LMU University Hospital, Munich, Germany
7Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
8Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
9Department of Chemistry, University of Toronto, Toronto, Canada
10Institute for Diagnostic and Interventional Radiology, University Hospital Cologne, Cologne, Germany
11Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
12Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

4:15 PM

Kelvin C. Mo, BA1*, Christine Y. Yeh, MS2,3,4*, Mark Hamilton, MD1,5, Jay Y Spiegel, MD, FRCPC6, Moksha Desai, MS1*, Zachary Ehlinger, MS1*, Warren D. Reynolds, BS1*, Eric Yang, MD, PhD1,7*, Michael G. Ozawa, MD, PhD1,7*, Yiyun Chen, PhD1*, Snehit Prabhu, PhD1*, Matthew J. Frank, MD, PhD1,5, Lori Muffly, MD1,8, Gursharan K. Claire, MPH1,5*, Sushma Bharadwaj, MD1,5, Saurabh Dahiya, MD, FACP1,9*, Katherine A. Kong, MS1*, Elena Sotillo, PhD1*, Bita Sahaf1*, Sylvia Plevritis, PhD2,10*, David B. Miklos, MD, PhD11,12, Crystal L. Mackall, MD1,13,14 and Zinaida Good, PhD1,2,14

1Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
2Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA
3Department of Genetics, Stanford University School of Medicine, Stanford, CA
4Department of Medicine, Stanford University School of Medicine, Stanford
5Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA
6University of Miami, Miami, FL
7Department of Pathology, Stanford University, Stanford, CA
8Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA
9Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
10Department of Radiology, Stanford University School of Medicine, Stanford, CA
11Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA
12Stanford Cancer Institute, Center for Cancer Cell Therapy, Stanford University, Stanford, CA
13Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
14Parker Institute for Cancer Immunotherapy, San Francisco, CA

4:30 PM

Tommaso Balestra, PhD1, Camilo Arenas Merizalde, BS1*, Robert K Chen1*, John Roach2*, Brian Bowser2*, Rachelle Salomon3*, Anthony Welch3*, Bonnie Yates, NP4*, Kristin Schaller5*, Michael R Verneris, MD5, Susanne H.C. Baumeister, MD6, Emily M. Hsieh, MD7, M. Eric Kohler, MD, Ph.D5, Katherine Tarlock, MD8, Steven Michael Devine, MD9, Richard Aplenc10,11, Nirali N. Shah, MD4, Terry J Fry, MD5 and Sarah K Tasian, MD10,12

1Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
2NCI, Biopharmaceutical Development Program, Frederick National Laboratory for Cancer Research, Frederick
3Biological Resources Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick
4Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
5Division of Hematology/Oncology/Bone Marrow Transplant and Center for Cancer and Blood Disorders, Children’s Hospital of Colorado, Aurora, CO
6Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
7Children's Hospital Los Angeles, Los Angeles, CA
8Division of Pediatric Hematology, Oncology, Bone Marrow Transplant & Cellular Therapy, Seattle Children's Hospital, Seattle, WA
9National Marrow Donor Program, Minneapolis, MN
10University of Pennsylvania School of Medicine, Philadelphia, PA
11Division of Oncology, Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, PA
12Division of Oncology & Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA

4:45 PM

Lisa M Niswander, MD, PhD1, Samantha McClellan2*, Diego Alberto Barcenas-Lopez, PhD3, Michael Yarnell, BSc4*, Shubhmita Bhatnagar, PhD2, Terry J Fry, MD5 and Sarah K Tasian, MD2,6

1Roswell Park Comprehensive Cancer Center, Philadelphia, PA
2Children's Hospital of Philadelphia, Philadelphia, PA
3Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA
4University of Colorado Anschutz Medical Campus, Aurora, CO
5Department of Pediatrics- Hematology, Oncology, and Bone Marrow Transplant, University of Colorado Anschutz Medical Campus, Aurora, CO
6Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA

5:00 PM

Takeshi Fujino1*, Jennifer Lewis2*, Bing-Yi Chen1*, Quinlan Sievers, MD, PhD2, Winson Cai1*, Sarah Yoo1*, Serena Mathew2*, Sydney Souness1*, Erin R. Burns1*, Jasmine S. Um1*, Elisa De Stanchina3*, Qing Chang2*, Besnik Qeriqi2*, Kevin Chen2*, PU Zhang1*, Susan Dewolf, MD4*, Alexander M. Lewis5*, Kenyon Weis5*, Brianna Gipson1*, Cynthia Castro2*, Nina Fox2*, Satoshi Kaito2*, Alyssa Fronk6*, Martin Akerman6*, Omar Abdel-Wahab, MD7 and Anthony F. Daniyan, MD8*

1Memorial Sloan Kettering Cancer Center, New York, NY
2Memorial Sloan Kettering Cancer Center, New York
3Memorial Sloan-Kettering Cancer Center, New York, NY
4Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY
5Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
6Envisagenics Inc., New York
7Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
8Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY

5:15 PM

Rui Zhang1*, Yifan Zhao1* and Mingfeng Zhao2

1Tianjin First Central Hospital, Tianjin, China
2Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

*signifies non-member of ASH